MEI Pharma Investor Relations Material

MEI Pharma Inc, formerly known as Marshall Edwards Inc., is a clinical-stage pharmaceutical company focusing on developing innovative therapies for cancer treatment. The company's drug development focus includes pracinostat, an oral histone deacetylase inhibitor aimed at treating advanced hematological diseases such as myelodysplastic syndrome. Additionally, MEI Pharma is working on ME-344, a mitochondrial inhibitor for the treatment of HER2-negative breast cancer and solid tumors, and Zandelisib (ME-401), an oral PI3K delta inhibitor for relapsed or refractory B-cell malignancies. Another key drug candidate is Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor intended for the treatment of acute myeloid leukemia (AML) and B-cell malignancies, being developed in agreement with Presage. It is headquartered in San Diego, California, and its shares are listed on the Nasdaq.